AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio) are set to unveil groundbreaking clinical data updates at the upcoming EASL™ Congress 2024. The companies will be presenting crucial findings from two Phase I trials of their leading molecule, AHB-137, with the aim of achieving a functional cure for chronic hepatitis B.
The clinical data of the Company’s HBV ASO molecule, AHB-137, will be showcased in two late-breaking posters, LBP-019 and LBP-043, at the annual European Association for the Study of the Liver (EASL™) Congress 2024 in Milan, Italy, from June 5th to 8th, 2024. These presentations will focus on new data from Phase I clinical studies conducted globally and in China, assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of AHB-137.
One of the posters, titled ‘Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B,’ will be presented by Prof. Edward J. Gane from the University of Auckland, New Zealand. The other poster, ‘A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B,’ will be presented by Wen Wang from The First Hospital of Jilin University, China.
AHB-137, an innovative unconjugated antisense oligonucleotide (ASO) developed using AusperBio’s Med-Oligo™ ASO technology platform, is showing promise in the pursuit of a functional cure for chronic hepatitis B. The compound’s impressive preclinical data was previously highlighted at the 2023 EASL™ conference. AHB-137 is currently undergoing Phase I trials at international multicenter sites and a Phase I/IIa trial in China, as part of its global development strategy.
Chronic Hepatitis B (CHB) is a prevalent liver disease affecting approximately 290 million individuals globally, leading to severe complications like cirrhosis and hepatocellular carcinoma. The quest for a functional cure for CHB remains a critical goal in the medical community, with AHB-137 at the forefront of innovative research and development efforts.
For more information on the scientific program of The International Liver Congress 2024 and access to abstracts, please visit the official EASL™ Congress website.
